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Influence of age at disease onset in the outcome of paediatric
systemic lupus erythematosus
Elodie Descloux1, Isabelle Durieu1,2, Pierre Cochat2,3, Denis Vital-Durand1,2, Jacques Ninet2,4,
Nicole Fabien5 and Rolando Cimaz2,3
Objectives. The aim of this study was to investigate the influence of age at disease onset in the outcome of paediatric SLE (pSLE).
Methods. Fifty-six patients with pSLE, divided into three groups (pre-pubertal, peripubertal and post-pubertal onset), were studied. The SDI
(SLICC/ACR Damage Index for SLE), patients’ characteristics, disease manifestations and treatments were compared using Fisher’s
exact test and Kruskal–Wallis test. Kaplan–Meier curves were constructed to compare the risk of damage occurrence.
Results. The risk of damage (SDI 51) significantly decreased when age at disease onset increased (89% in pre-pubertal pSLE, 57%
in peripubertal pSLE and 38% in post-pubertal pSLE). This excess of risk was found in all disease duration intervals studied (1–3, 3–5, 5–8,
8–10, >10 years) and at the end of follow-up. Kaplan–Meier curves indicated a higher and earlier risk of damage in younger patients. Young
children showed higher frequency of autoimmune family history. The frequency of neuropsychiatric disorders and damages decreased
with age at disease onset (P< 0.05). Cumulative duration of high-dose prednisone (> 0.5 mg/kg/day) and number of immunosuppressive
drugs used that seem to contribute to damage significantly increased when age at disease onset decreased.
Conclusions. The risk of damage is inversely correlated with age at disease onset in pSLE. The poorer outcome observed in younger
children may be explained by a more severe disease expression, may be a higher infectious susceptibility, and a more aggressive therapy,
particularly within the first 6 months of disease course.
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Introduction
SLE is a multisystem inflammatory autoimmune disease that
usually affects young women, with 10–17% of cases occurring in
childhood [1–8]. Several studies suggest that both clinical and
biological features of SLE are influenced by age at disease
onset, and that SLE may be more severe in childhood onset
than in adulthood onset [1–5, 8–13].
As mortality decreased remarkably over the last few decades
[14, 15] probably secondary to better recognition and therapeutic
approaches, children and adolescents with paediatric-onset SLE
(pSLE) are now faced with considerable morbidity due to sequelae
of disease activity, side effects of medications and co-morbid con-
ditions [12, 13, 16–19]. Risk factors of poor prognosis have been
reported in pSLE, such as male sex [3, 20–23] and non-Caucasian
origin [1, 22, 24], although data are controversial [9, 25]. Several
authors found a significant correlation between damage and the
presence of aPLs [12, 19, 26], some manifestations like acute
thrombocytopenia [12], neuropsychiatric symptoms [16], hyper-
tension especially in patients with diffuse proliferative glomerulo-
nephritis [1, 9, 17] and cumulative disease activity [12, 18].
In adults with SLE, increasing age and longer disease duration
have been associated with damage [27–30]. However, the influence
of age at disease onset in pSLE prognosis remains unclear [9, 12,
15, 16, 18, 23, 31]. The primary objective of this study was to
investigate the relationship between outcome and age at disease
onset in pSLE. To assess the difference of outcome severity,
three groups were compared according to age at disease onset
(pre-pubertal, peripubertal or post-pubertal onset).
Methods
Study design and patient selection
Medical charts of all patients followed for SLE at the University
Hospital of Lyon (France) in paediatric consultation and/or hos-
pitalization units between 1996 and 2006 or in internal medicine,
nephrology, rheumatology, dermatology and cardiology units
between 2000 and 2006 were reviewed. The inclusion criteria
were: (i) onset of SLE symptoms 416 years of age, (ii) at least
4 of 11 classification criteria for SLE [32] and (iii) disease duration
512 months (except for fatal cases). This cohort of patients has
already been studied [19] and was followed up regularly until June
2006. The study was approved by the local ethics committee (The
Committee of Protection of the Persons of the Hospices Civils of
Lyon). Patients were divided into three groups based on age at
disease onset: the pre-pubertal group included boys of age 49
years and girls 48 years, the peripubertal group included boys
of age >9 and <14 years and girls >8 and <13 years and the post-
pubertal group included boys of age 514 years and girls 513
years. The clinical and laboratory characteristics of each group,
their treatment and outcome were compared.
Data collection
All data collected from medical charts were recorded on a stan-
dardized data form. The following parameters have been consid-
ered for each patient: age at disease onset (first symptoms related
to SLE), sex, ethnicity, positive family history for autoimmune
disease (in first- and second-degree relatives), clinical and labora-
tory characteristics during the first month and during follow-up,
disease duration, treatment and outcome. Clinical manifestations
and results of laboratory tests were monitored every month or
every 3 months when disease was active and every 6 months or
12 months when disease was quiescent.
ANAs were determined by IIF and anti-dsDNA antibodies by
IIF using Crithidia luciliae as substrate and by Farr test. Each
patient had a mean of 6.9 3.3 (median 6) determinations of
aPLs. The aPL detection was performed at least twice except in
one patient (one aPL-negative sample) who died of pulmonary
embolism secondary to anti-thrombin III deficit, 2 months after
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pSLE onset. In the aPL-positive group, as previously described
[19], we distinguished transient aPL [positive detection once
or several times, but not confirmed (negative) at 6–12 weeks of
interval], intermittent aPL [positive detection at least twice and
confirmed at 6–12 weeks of interval, with period(s) of negative
detection] and persistent aPL (positive detection at least twice
and confirmed at 6–12 weeks of interval, without any period
of negative detection). LAC was detected using international
recommendations [33], and aCLs were measured by commercial
(BioRad–Sanofi Pasteur) or in-house immunoenzymatic assay
(ELISA). Threshold detection was >12 UMPL and >24 UGPL
for aCL, IgM and IgG, respectively, for samples collected from
2000 to 2006, and >11 UMPL and >23 UGPL for aCL, IgM and
IgG, respectively, for samples collected before 2000. Anti-2
glycoprotein I was not considered as these aPLs were not regularly
detected.
In order to evaluate the severity of pSLE outcome, we cons-
idered the value of SDI (SLICC/ACR Damage Index or SLICC/
ACR for SLE). The SDI score measures the accumulated and
irreversible damage that result from both disease activity and
adverse effects of medications. This score, ranging from 0 to 47
(41 items), includes the assessment of 12 organ systems [34, 35].
To eliminate the effects of disease duration that were shown to
correlate with damage accumulation [16, 17], the SDI score was
assessed at regular time intervals: 1–3, 3–5, 5–8, 8–10, >10 years
and at the end of follow-up. The delay of occurrence and the type
of damage were recorded for each patient. We also considered
the mortality rate and causes of death. The main outcome
parameter was the risk of damage (SDI 51) or death related
to pSLE.
Statistical analysis
All data were analysed using R software (R Development Core
Team) version 2.6.0. Results were expressed as mean S.D. and
medians for continuous variables, and as numbers (percentages)
for binary and categorical variables. Patients with pre-pubertal,
peripubertal and post-pubertal pSLE onset were compared using
the Fisher’s exact test for categorical variables and the Kruskal–
Wallis test for continuous variables. To compare the delay of
damage occurrence according to age at disease onset, time-to-
damage end points were plotted using life table method, and
Kaplan–Meier curves were compared by log rank test. P-values
<0.05 were considered significant.
Results
Fifty-six patients with pSLE were included in this study: 39 girls
(70%) and 17 boys (30%). The mean age at pSLE onset was
12.6 3.2 years (median 13 years). Nine children (16%) developed
the first symptoms of pSLE before puberty onset, 21 (38%) during
the peripubertal period and 26 (46%) during the post-pubertal
period. Sex ratio and ethnicity were not significantly different
between the three age groups at disease onset (Table 1).
Although the values did not reach statistical significance, a
positive family history for autoimmune disease (particularly
SLE) was more frequently reported in patients with pre- and
peripubertal disease onset than in patients with post-pubertal
onset. The risk of damage (SDI 51) in pSLE was high (30/56,
54%) and significantly decreased with age at disease onset (89% in
the pre-pubertal group, 57% in the peripubertal group and 38%
in the post-pubertal group). The disease duration was not
statistically significant in the three groups (mean 6.6–8 years).
Clinical and biological features in patients with pre-,
peri- and post-pubertal pSLE onset
Disease manifestations among the three age groups of pSLE
onset were different during the first month of disease and during
follow-up (Fig. 1). The initial presentation of pSLE frequently
involved haematological and renal organ systems in children
with pre-pubertal disease onset. During the follow-up, the
frequency of neuropsychiatric involvement (epilepsy, cerebral
vasculitis and cerebrovascular accident in particular) increased
when age at disease onset decreased (P¼ 0.037). The frequency
of ANAs (100%), anti-dsDNA antibodies (88–95%) and aPLs
(50–62%) were comparable in the three groups. Different types
of aPLs (LAC and aCL) were often associated (16/56, 29%), but
aCLs (27/56, 48%) were more frequent than LACs (20/56, 36%).
The frequency of persistent and intermittent aPL was roughly
similar in the three groups, whereas transient aPLs were
significantly more frequent in peripubertal pSLE (62%) than in
pre- (0%) or post-pubertal pSLE (15%). Ten patients (18%)
developed APS (three in the pre-pubertal group, one in the
peripubertal group and six in the post-pubertal group, P¼ 0.09).
The risk of thrombosis (most frequently venous) was high in the
three groups (44, 24 and 35% in the pre-, peri- and post-pubertal
groups, respectively), but no statistical difference was seen.
Severe infections were reported in 16 (29%) patients (12 septi-
caemia, 11 pneumonia, 2 pyelonephritis, 2 myositis, 1 meningitis)
implicating bacteria (in particular Staphylococcus aureus, 14 cases)
rather than other microorganisms (Myxovirus influenzae and
Cryptococcus neoformans, one case each). All infected patients
had received corticosteroids or another immunosuppressive treat-
ment. The frequency of infectious complications was higher in
younger patients, although not significantly so (44, 38 and 15%
in pre-, peri- and post-pubertal pSLE, respectively).
TABLE 1. Characteristics and outcome of 56 patients with pSLE according to age at disease onset
Pre-pubertal onset
n¼9 (16%)
Peripubertal onset
n¼21 (38%)
Post-pubertal onset
n¼26 (46%) Pa
Age at disease onset, years
Girls 48 > 8 and < 13 513
Boys 49 > 9 and < 14 514
Mean (median) range 6.9 (7.4) 3.8–8.9 12.1 (12.3) 9–13.5 15 (15.5) 13–16.8
Sex ratio (female/male) 2 (6/3) 2 (14/7) 2.7 (19/7) NS
Ethnicity
Caucasian 4 (44) 14 (67) 14 (54) NS
African 4 (44) 3 (14) 5 (19) NS
Asian – – 2 (8) NS
Middle East – 1 (5) – NS
Unknown 1 (11) 3 (14) 5 (19) NS
Autoimmune family history 2 (22) 6 (29) 1 (4) 0.048
SLE family history 2 (22) 2 (10) 1 (4) NS
Disease duration, mean (median) range, years 8 (8) 2–12.2 6.6 (6.3) 1.5–14 8 (5.9) 0.2–26.2 NS
Risk of damage, SDI 51 8 (89) 12 (57) 10 (38) 0.032
Death 2b (22) 1c (5) 2 (8) NS
Values are given as n (%), unless otherwise mentioned. aDifferences between pre-, peri- and post-pubertal groups with P-value > 0.05 were not
significant (NS). bA third patient with pre-pubertal pSLE died a few months after the end of the study. cA girl with peripubertal pSLE committed suicide
although SLE was benign and quiescent since > 1 year. Her death was not considered in these results.
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Outcome according to age at disease onset
Most of the children (86%) developed damage within 10 years
(62% during the first 5 years, 24% during the next 5 years of
disease course). Kaplan–Meier curves showed that the percentage
of damage-free patients (SDI¼ 0) was significantly different
between the three groups, decreasing when age at disease onset
increased (Fig. 2). The slope of the curves decreased when age at
pSLE onset increased as well, suggesting a higher and earlier risk
of damage in younger patients. These results indicate that the risk
of damage is inversely correlated with age at pSLE onset. The risk
of damage (SDI 5 1) or death was calculated at regular time
intervals (1–3, 3–5, 5–8, 8–10 and > 10 years) and at the end of
follow-up (Fig. 3). We found an excess of risk inversely correlated
with age at disease onset in all disease duration intervals.
After a comparable disease duration (mean 6.6–8 years), mean
SDI score was 1.3 (range 0–7, median 1). The SDI score decreased
with age at disease onset, but not significantly so [mean (median):
1.78 (2), 1.88 (1), 1.08 (0); range 0–4, 0–5 and 0–7 in the pre-,
peri- and post-pubertal groups, respectively). Analysis of
damage repartition revealed that the most frequent organ systems
affected in pSLE were renal (20%), neuropsychiatric (16%),
musculoskeletal and skin (13% each) (Table 2). Renal and
neuropsychiatric systems were affected early, during the first
years of disease course. Although the frequency of renal damage
was high but not significantly different between the three groups,
the frequency of neuropsychiatric damage was higher in the pre-
pubertal than in the peri- and post-pubertal groups (P¼ 0.014).
The frequency of skin and ocular damages decreased with age at
disease onset also, even though not significantly (P¼ 0.06 and
P¼ 0.44, respectively). All cataracts (n¼ 4) and retinopathies
(n¼ 2) occurred in patients treated with corticosteroids  anti-
malarials.
Six patients died (11%). In half of the cases, the event took
place during the first year after diagnosis. The causes of mortality
were often multi-factorial, associating severe SLE flares, infectious
complications and thrombotic events in the three age groups [19].
Description of therapies and outcome according to
medical treatment
Treatments of patients are summarized in Table 3. The cumulative
duration of treatment with high-dose prednisone (> 0.5mg/kg/
day) significantly increased when age at disease onset decreased.
Multiple immunosuppressive treatments were successively
administered in all patients with pre-pubertal pSLE and more
frequently in peripubertal (67%) than in post-pubertal (39%)
0
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FIG. 1. Clinical and biological manifestations in 56 patients with pSLE according to age at disease onset.
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FIG. 2. Kaplan–Meier type plot of time to damage occurrence in pSLE according to
age at disease onset.
0
20
40
60
80
100
1–3 3–5 5–8 8–10 >10
follow-up
Disease duration (years) 
Pa
tie
n
ts
 
w
ith
 
da
m
ag
e 
(S
DI
≥1
) o
r 
de
at
h 
(%
) Pre-pubertal onset
Peripubertal onset
Post-pubertal onset
All age classes
Number          
of patients    n=56              n=51               n =46              n =28            n =20     n =56
P < 0.05
(Fisher’s test)
end of
FIG. 3. Risk of damage (SDI 51) or death in 56 patients with pSLE according to
age at disease onset.
Influence of age at disease onset in pSLE outcome 781
 at U
niversitÃ  degli Studi di Firenze on October 31, 2012
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
pSLE (P¼ 0.022). Most of the patients required a successive
administration of cyclophosphamide, mycophenolate mofetil
and/or AZA. Analysis of initial therapies showed that high-dose
prednisone (> 0.5mg/kg/day) for the first 6 months, intravenous
methylprednisolone pulses and/or another immunosuppressive
treatment within the first 6 months, were more frequently required
when pSLE started during the pre-pubertal period (67%) than
during the peripubertal (57%) or the post-pubertal period (23%)
(P¼ 0.029). Chronic haemodialysis was necessary in nine cases
(16%) and renal transplantation in three cases (5%), with no
significant difference according to age at disease onset.
We also considered relationships between treatments and risk
of damage (SDI 5 1) in pSLE. The occurrence of damage was
significantly (P< 0.001) correlated with the use of intravenous
methylprednisolone pulses and the cumulative duration of
treatment with high-dose prednisone (>0.5mg/kg/day) but not
TABLE 2. Frequency of damages considered by the SDI in pre-pubertal, peripubertal and post-pubertal pSLE
Damagea
All patients
(n¼56)
Pre-pubertal onset
(n¼9)
Peripubertal onset
(n¼21)
Post-pubertal onset
(n¼ 26) Pb
Ocular 6 (11) 2 (22) 2 (10) 2 (8) NS
Any cataract 4 1 2 1
Retinal change 2 1 0 1
Neuropsychiatric 9 (16) 4 (44) 4 (19) 1 (4) 0.014
Cognitive impairment or major psychosis 3 1 2 0
Seizures requiring therapy for 6 months 3 2 1 0
Cerebrovascular accident 3 1 1 1
Renal 11 (20) 1 (11) 5 (24) 5 (19) NS
End-stage renal disease 9 (16) 1 (11) 4 (19) 4 (15) NS
Pulmonary 1 (2) 1 (11) 0 (0) 0 (0) NS
Pulmonary fibrosis 1 1 0 0
Cardiovascular 3 (5) 1 (11) 1 (5) 1 (4) NS
Myocardial infarction 2 1 0 1
Pericarditis for 6 months 1 0 1 0
Peripheral vascular 0 (0) 0 (0) 0 (0) 0 (0) NS
Gastrointestinal 4 (7) 0 (0) 2 (10) 2 (8) NS
Infarction or resection of bowel, spleen, liver or gall blader 3 0 2 1
Mesenteric insufficiency 1 0 0 1
Musculoskeletal 7 (13) 1 (11) 4 (19) 2 (8) NS
Muscle atrophy or weakness 4 0 4 0
Deforming or erosive arthritis 1 0 0 1
Osteoporosis with fracture 2 1 0 1
Avascular necrosis 3 0 1 2
Skin 7 (13) 3 (33) 3 (14) 1 (4) NS
Scarring chronic alopecia 4 3 1 0
Extensive scarring or panniculum other than scalp and pulpe space 1 0 1 0
Skin ulceration (excluding thrombosis) for > 6 months 2 0 1 1
Premature gonadal failure 1 (2) 0 (0) 0 (0) 1 (4) NS
Diabetes 1 (2) 0 (0) 0 (0) 1 (4) NS
Malignancy 0 (0) 0 (0) 0 (0) 0 (0) NS
Values are given as n (%), unless otherwise mentioned. aThe list of damages presented in this table only comprises the damages developed by the patients included in our study. All the 41 items of
the SDI are not listed in this table. bDifferences between pre-, peri- and post-pubertal groups with P-value > 0.05 were not significant (NS).
TABLE 3. Summary of drug therapies in three age classes of pSLE
Drug therapies
Pre-pubertal
onset (n¼ 9)
Peripubertal
onset (n¼21)
Post-pubertal
onset (n¼ 26) Pa
Anti-malarial treatment 7 (78) 13 (62) 11 (42) NS
Corticosteroid treatment 8 (89) 19 (90) 24 (92) NS
Cumulative duration of corticosteroid therapy, mean (median, range), years 6 (6.3, 0.1–12.2) 5.8 (5.5, 1.5–13) 5.8 (5.3, 0.2–19) NS
Cumulative duration of high-dose prednisone (>0.5 mg/kg/day),
mean (median, range), months
12.8 (9, 0.2–36) 10.3 (6, 3–36) 5.5 (5.5, 0.2–12) 0.049
Intravenous methylprednisolone pulses (10–30 mg/kg/day) 6 (67) 12 (57) 11 (42) NS
No. of pulses: mean (median, range) 4.8 (4.5, 2–9) 4.7 (3.5, 2–9) 3.5 (3, 3–6) NS
Immunosuppressive treatments 6 (67) 12 (57) 18 (69) NS
Intravenous cyclophosphamide pulses (500–1000 mg/m2) 6 (67) 9 (43) 8 (31) NS
No. of pulses: mean (median, range) 9.2 (7.5, 6–19) 6.8 (6, 2–13) 7.5 (8.5, 10–14) NS
Oral cyclophosphamide 1 (11) 2 (10) 1 (4) NS
AZA 3 (33) 6 (29) 8 (31) NS
No. of months: mean (median, range) 5.3 (5, 5–6) 18.2 (13, 12–36) 15.6 (6.5, 3.8–76) 0.027
Mycofenolate mofetil 4 (44) 6 (29) 7 (27) NS
No. of months: mean (median, range) 35.8 (39, 14–51) 12.7 (7, 5–33) 32.4 (25, 3–67) NS
Cyclosporin 4 (44) 4 (19) 4 (15) NS
No. of months: mean (median, range) 29.8 (20, 1–78) 11.8 (13.5, 2–18) 27.5 (29, 16–36) NS
MTX 1 (11) 1 (5) 1 (4) NS
Multiple immunosuppressive treatmentsb 6 (100) 8 (67) 7 (39) 0.022
No.: mean (median, range) 3 (3, 2–5) 2.2 (2, 1–5) 1.6 (1, 1–4) 0.020
Intravenous immunoglobulins 5 (56) 5 (24) 2 (8) 0.010
Plasma exchanges 1 (11) 3 (14) 2 (8) NS
Values are given as n (%), unless otherwise mentioned. aDifferences with P-value > 0.05 were not significant (NS). bTwo immunosuppressors were successively required in 11 cases, three in 6
cases, and four or five in 2 cases each.
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with the number of intravenous methylprednisolone pulses and
the cumulative duration of corticosteroid therapy (whatever the
dose). The use of another immunosuppressive treatment increased
the risk of damage (P¼ 0.012), particularly if multiple drugs were
associated. The risk of damage was correlated with a longer
administration of AZA (P¼ 0.049) but not with the number
of cyclophosphamide pulses, or the number of months of
mycophenolate mofetil administration.
Discussion
The main objective of this study was to investigate the influence of
age at disease onset on the outcome in pSLE. We found that
the risk of damage (SDI 51) significantly decreased when age
at disease onset increased (89% in the pre-pubertal group, 57%
in the peripubertal group and 38% in the post-pubertal group).
This excess of risk, inversely correlated with age at disease onset,
was found in all disease duration intervals studied (1–3, 3–5, 5–8,
8–10 and >10 years) and at the end of follow-up. Kaplan–Meier
curves confirmed that the risk of damage was inversely correlated
with age at pSLE onset, indicating a higher and earlier risk of
damage in early-onset disease. Moreover, despite the absence
of statistical significance, the SDI score was higher when pSLE
began early.
Several studies suggest that SLE tends to be more severe in
childhood onset than in adulthood onset [1–5, 8–13]. Children
with pSLE were found to have more active disease at presentation
and over time, especially active renal disease, more intensive drug
therapy and more damage accrual than do adults with SLE [13].
However, the influence of age at disease onset in children remains
unclear and has rarely been studied in detail previously.
Pluchinotta et al. [36] recently found that the cumulative disease
activity at diagnosis as measured by the SLEDAI was significantly
higher in infantile (42 years) than in pre-pubertal (2–10 years)
and post-pubertal (11–16 years) pSLE onset, but long-term
evolution was not considered. In a series of 66 patients, Brunner
et al. [12] found that age at pSLE diagnosis was not an important
predictor of disease damage as measured by the SDI after a short
period of follow-up (mean 3.3 2.04, range 0.5–7.9 years).
In another study of 57 patients with pSLE, no significant associa-
tion was observed between age at diagnosis and damage
accrual [18] measured using a modified SDI (by adding the item
growth failure). The relationship between age at disease onset
and death related to pSLE is also controversial [9, 15, 23].
Altogether, our results suggest that the risk of damage is
inversely correlated with age at disease onset in pSLE. These
findings contrast with those reported in adults for whom increas-
ing age and longer disease duration are correlated with damage
[27–30]. Hence, the severity of SLE outcome seems to follow
a bimodal trend with higher frequency of damage in younger chil-
dren and older adults, and lower frequency of damage in
intermediate ages.
Given the importance of hormonal factors (e.g. sex hormones)
in SLE pathogenesis, age thresholds were defined considering
the age at puberty onset. As our study was retrospective and
standardized criteria to determine Tanner pubertal stage [37, 38]
were not available in all medical charts, the theoretical ages of
puberty were considered taking also into account the earlier
pubertal development in girls [39–42]. As there are no data
permitting to assess the normal age range of pubertal onset in
France, like in many countries, the usual ranges of 8–13 years in
girls and 9–14 years in boys were used [37, 38]. To strengthen our
results, we compared the pre-, peri- and post-pubertal groups
using the same age brackets for the two sex (49, >9 and <14
and 514 years, respectively) and the differences observed were
roughly similar (data not shown). In particular, the risk of
damage was inversely correlated with age at pSLE onset, with
robust significance (P¼ 0.015).
In our study, children with pre-pubertal pSLE showed a higher
frequency of haematological and renal involvement during
the first month, and developed more frequently neuropsychiatric
disorders that could lead to disease damage. As reported in
another study [36], patients with post-pubertal pSLE presented
more specific (e.g. cutaneous and musculoskeletal), like in
adults. The peripubertal group had an intermediate presentation.
These different patterns of pSLE presentation according to age at
disease onset could be explained by genetic, immune and hormo-
nal factors. Patients with early-onset disease may be characterized
by a partial immaturity of their immune system and a stronger
genetic predisposition to develop pSLE, as suggested in our series
by a relatively frequent positive family history for autoimmune
disease in younger patients, whereas the influence of sex hormones
may play a predominant role in patients with later onset disease.
The main causes of death in SLE (with childhood or adulthood
onset) are severe SLE flares, thromboses and infections ( 25%
each) [10, 15, 19, 43, 44]. An increasing proportion of death is
linked to thromboses [10] and there is a strong association
between aPL and thromboses [10, 19, 45–48]. Previously, we
found that the risk of thrombosis in pSLE was significantly
higher in the presence of aPLs [odds ratio (OR)¼ 6.42], especially
if they persisted over time, and the risk of damage (SDI 51) was
higher in aPL-positive than in aPL-negative patients (OR¼ 3)
[19]. In the present study, the frequency of aPL and thrombosis
was high but comparable in the three age groups. The frequency
of severe infections, decreasing with age at disease onset, may
partially explain the worse survival rate observed in pre-pubertal
pSLE [15].
In accordance with other studies, the most frequent organ
systems affected in pSLE were renal (20%), neuropsychiatric
(16%), musculoskeletal and skin (13% each) [11, 13, 16]. Neuro-
psychiatric involvement seems to be associated with damage in
pSLE [16] and we found that the frequency of neuropsychiatric
damage, like the global risk of damage and the SDI value,
decreased with age at disease onset. Similar variations of
frequency were observed for skin and ocular damages also.
There is evidence that some damages (e.g. renal, neuropsychiatric)
are more likely to be due to disease activity, as they appear earlier
during disease course [12, 18], and that others are more likely to be
due to adverse effects of treatments [16–18]. For instance, all
ocular damages occurred under corticosteroid and anti-malarial
therapies in our series.
The prognostic impact of therapies remains controversial in
pSLE [12, 16–18]. In our study, long-term use of high-dose pred-
nisone and successive administration of multiple immuno-
suppressive agents were correlated with damage. Differences in
therapeutic strategies may explain several age-related differences
observed in pSLE outcome. We found that the cumulative
duration of high-dose prednisone (> 0.5mg/kg/day) and the
number of immunosuppressive drugs used significantly increased
when age at disease onset decreased although disease duration was
comparable in the three age groups. Early intensive therapies
were more frequently administered in early-onset disease. Con-
sequently, the poorer outcome observed in children, particularly
with early-onset pSLE, is more likely to be linked to adverse
effects of intensive therapies than to insufficiently aggressive treat-
ment. Most severe patients had most aggressive therapy but we do
not know if the poor outcome in early-disease onset is more likely
to be due to adverse effects of treatment, rather than the severe
disease itself.
Although the small size of patient groups, particularly the
pre-pubertal one, constitutes a limitation of the study, our results
suggest that the risk of damage in pSLE is inversely correlated
with age at disease onset (pre-pubertal> peripubertal> post-
pubertal). The poorer outcome observed in younger children
may be explained by a stronger genetic predisposition, a more
severe disease expression (e.g. more frequent neuropsychiatric
disorders), a higher infectious susceptibility and a more aggressive
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therapy, particularly within the first 6 months of disease course.
Combined strategies should be considered to improve the
prognosis in pSLE, including the rapid control of disease activity
(in particular, neuropsychiatric manifestations), the rapid
management of infections [50] and thromboses, and the preven-
tion of therapeutic adverse effects.
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Rheumatology key messages
 Risk of damage is inversely correlated with age at disease onset in
pSLE.
 Frequency of neuropsychiatric disorders, duration of high-dose
prednisone and number of immunosuppressors used are higher
in younger patients.
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